WALTHAM,
Mass., Dec. 19, 2023 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:
SNDX), a clinical-stage biopharmaceutical company developing an
innovative pipeline of cancer therapies, today announced the
closing of its previously announced underwritten public offering of
12,432,431 shares of its common stock, which includes the exercise
in full of the underwriters' option to purchase 1,621,621
additional shares. The public offering price of each share of
common stock was $18.50. The
aggregate gross proceeds to Syndax from this offering, before
deducting underwriting discounts and commissions and estimated
offering expenses, were approximately $230.0
million. Following the closing of the Offering, Syndax has
84,809,736 shares issued and outstanding as of December 19, 2023.
Goldman Sachs & Co. LLC, J.P. Morgan, TD Cowen and Stifel
acted as joint book-running managers for the offering. B. Riley
Securities acted as manager for the offering.
The shares were offered pursuant to a "shelf" registration
statement previously filed and declared effective by the Securities
and Exchange Commission (SEC). A final prospectus supplement and
accompanying prospectus relating to the offering were filed with
the SEC and are available on the website of the SEC at www.sec.gov.
Copies of the final prospectus supplement and accompanying
prospectus relating to the offering may be obtained from: Goldman
Sachs and Co. LLC, Attention: Prospectus Department, 200 West
Street, New York, NY 10282,
telephone: 866-471-2526, facsimile: 212-902-9316 or by emailing
Prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, telephone:
(866) 803-9204, or by emailing prospectuseq_fi@jpmchase.com; Cowen
and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by emailing
Prospectus_ECM@cowen.com or by telephone at (833) 297-2926; or
Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus
Department, One Montgomery Street,
Suite 3700, San Francisco,
California 94104, by telephone at (415) 364-2720 or by
emailing syndprospectus@stifel.com.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Syndax
Syndax Pharmaceuticals is a clinical stage biopharmaceutical
company developing an innovative pipeline of cancer therapies.
Highlights of the Company's pipeline include revumenib, a highly
selective inhibitor of the menin–KMT2A binding interaction, and
axatilimab, a monoclonal antibody that blocks the colony
stimulating factor 1 (CSF-1) receptor. For more information, please
visit www.syndax.com or follow the Company on
Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend," "believe" and similar expressions (as well as
other words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Syndax's expectations
and assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. Factors that may cause Syndax's actual results to
differ from those expressed or implied in the forward-looking
statements in this press release are discussed in Syndax's filings
with the SEC, including the "Risk Factors" sections contained
therein, as well as the risks identified in the registration
statement and the final prospectus supplement relating to the
offering. These forward-looking statements are based on Syndax's
expectations and assumptions as of the date of this press release.
Except as required by law, Syndax assumes no obligation to update
any forward-looking statements contained herein to reflect any
change in expectations, even as new information becomes
available.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-announces-closing-of-public-offering-of-common-stock-and-exercise-in-full-of-the-underwriters-option-to-purchase-additional-shares-302019482.html
SOURCE Syndax Pharmaceuticals, Inc.